NeuraMedica is an early-stage Oregon Health and Science University (OHSU) startup focused on the development of a novel, bioabsorbable surgical clip for durotomy closure.
Rachel Dreilinger is a biomedical engineer with experience in startups, consulting, lab automation, DNA synthesis and medical device development. She founded the consultancy Hayoka Designs, LLC in 2008 and Radical R&D, LLC in 2014 specializing in medical device design for clients such as OHSU, Bayer Healthcare and Acute Innovations. She has extensive experience in orthopedics, neurosurgery, dentistry, bioabsorbable polymers, mechanical design and all phases of product development. She received her BS degree in Bioengineering from the University of California, San Diego (UCSD) in 1999.
Neil Roundy, MD is a neurosurgeon with Oregon Neurosurgery Specialists, a private-practice group in Eugene, OR. Dr. Roundy has ongoing research projects in advanced Neuroimaging using High-Field 7 Tesla MRI; mobile technology in education; pre-operative, multispectral, high-resolution 3D modeling for simulated surgical planning, and bioabsorbable dural closure device for minimally-invasive surgery. His work interests include skullbase surgery, minimally-invasive intracranial and spinal surgery and neuroendoscopy. He graduated from University of Arizona in 2007.
Michael Tippie is an executive with more than 25 years of operational, venture and consulting experience. Most recently, Michael was CEO of TomegaVax, which was merged with Vir Biotechnology in 2016 and immediately thereafter did a $150 million Series A venture financing (ARCH Ventures, Gates Foundation). Michael has held senior executive roles in seven start-ups and has managed accounting, market research, business development and sales staffs. He has completed complex deals with large pharma companies as well as numerous private and public financings (including IPOs). Michael’s venture experience comes from stints at Norwest Venture Partners ($4 billion megafund), Medical Innovation Partners ($35 million seed-stage medical device focused fund) and Milk Street Ventures (secondary venture purchases). Michael holds a BA in Chemistry from Reed College and an MS in Chemistry from the University of Washington as well as an MBA from the MIT Sloan School of Management.
Coni Rosati is a bioengineer and business executive with over 30 years of experience developing applications and products that include drug delivery, wound care, sustaining organs, veterinary, aesthetics, wearables, and bedside or patient-worn sensor systems. She co-founded multiple start-ups and worked in large multinationals to develop, launch, diversify and spin out new medical technologies. She has been successful in raising funds from grants, venture, federal and private sources. She also develops and executes strategies that deliver growth and profitability, and works with investment bankers to successfully sell businesses.
The NeuraMedica Dural Clip is an innovative advancement in durotomy closure. The dura mater is a membrane that covers and protects the brain and spinal cord and also contains the circulating cerebrospinal fluid (CSF). When this membrane is cut, either deliberately (tumor resection) or accidentally (incidental durotomy) the CSF spills out and must be repaired quickly. Typically a surgeon will close the dura using fine suture under magnification. It is a tedious and time-consuming process.
NeuraMedica is developing the Dural Clip for use by both neurosurgeons and orthopedic spine surgeons for closure of the dura mater. The clips are bioabsorbable (dissolve in the human body) and radiolucent (invisible to imaging) and they are applied with a custom, disposable applicator. The Dural Clip is currently being tested in animal models and is not available for human use. NeuraMedica is dedicated to commercializing this device as well as other neurosurgery-related products.
FUNDING & PRESS
NeuraMedica has received development grants from the Oregon Health and Science University (OHSU) Biomedical Innovation Program (BIP) through the Oregon Clinical and Translational Research Institute (OCTRI).
NeuraMedica is also receiving gap funding from the Oregon Nanoscience and Microtechnologies Institute (ONAMI).